{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"336","upperLimit":"808","value":"532"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"}],"units":"Participants"}],"description":"Association between overall survival and standardized phase angle will be evaluated using a Cox proportional hazards model.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment. Patients with AML undergo a second measurement just prior to the nadir marrow. Patients also undergo bioelectrical impedance measurements prior to any invasive procedures (bone marrow biopsy, leukapheresis, PICC line placement, etc.).\n\nbioelectric impedance analysis: Undergo bioelectric impedance analysis","id":"OG000","title":"Diagnostic (Bioelectric Impedance Analysis)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Days"}